STRIDE Study for Inflammatory Bowel Disease Now Enrolling Patients

Seattle Children’s, in partnership with the Allen Institute for Immunology, launched a first-of-its-kind clinical study to better understand how and why inflammatory bowel disease (IBD) begins, with the ultimate goal to provide targeted therapies to children who suffer from IBD. The Seattle STRIDE study is led by Seattle Children’s Research Institute’s Dr. Hengqi (Betty) Zheng, principal investigator, Center for Immunity and Immunotherapies, and Dr. David Suskind of the Center for Clinical and Translational Research, co-principal investigator.

The study is the first pediatric trial to deploy novel techniques (single cell spatial transcriptomics and single cell multi-omics) to understand how genes and other molecules behave in individual cells of patients who haven't been treated yet.

Researchers hope that the information gained from the study will not only improve treatment options, but also inform the decisions of how to treat individual patients, reducing the number of treatments patients must undergo.

The trial is recruiting participants ages 6 to 18 years old over a three-year period. While the majority of study participants will learn of the trial via Children’s Emergency Department admissions, community providers are welcome to refer any patients with suspected diagnoses of Crohn's disease, ulcerative colitis, or indeterminate colitis. The study will collect additional patient biopsies and blood samples at initial diagnosis and over the course of the study. See the study website for more information.